CCXI News and Press, ChemoCentryx Inc. From 03/03/22

CCXI got its first approval last October. Revenue and patient uptake has been good. A few more quarters will be needed to assess the company properly. For further details see: ChemoCentryx: Good Post-Approval Performance, But Needs More Time

Gainers: Organogenesis (NASDAQ:ORGO) +24%. CytomX Therapeutics (NASDAQ:CTMX) +13%. X4 Pharmaceuticals (NASDAQ:XFOR) +13%. MannKind (NASDAQ:MNKD) +10%. Allied Healthcare (NASDAQ:AHPI) +6%. Losers: Karyopharm Therapeutics (NASDAQ:KPTI) -31%. Bright Health Grou...

Karyopharm Therapeutics (NASDAQ:KPTI) -29% after US Regulatory update on Selinexor in advanced or recurrent endometrial cancer. GoHealth (NASDAQ:GOCO) -24% on expecting Q4 revenue below estimates. Bright Health (NYSE:BHG) -10% on Q4 earnings release. Telefonaktie...

ChemoCentryx, Inc. (CCXI) Q4 2021 Earnings Conference Call March 1, 2022 05:00 p.m. ET Company Representatives Dr. Thomas Schall - Chairman, President and Chief Executive Officer Susan Kanaya - Executive Vice President, Chief Financial and Administrative Officer Tausif Butt - Executive Vice P...

ChemoCentryx press release (NASDAQ:CCXI): Q4 GAAP EPS of -$0.58 in-line. Revenue of $2.32M (-46.8% Y/Y) misses by $1.58M. Shares -14.6%. For further details see: ChemoCentryx GAAP EPS of -$0.58 in-line, revenue of $2.32M misses by $1.58M

-- Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS ® (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following US Food and Drug Administration (FDA) approval in ANCA-associated vasculitis -- -- TAVNEOS also approved...

ChemoCentryx (NASDAQ:CCXI) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close. The consensus EPS Estimate is -$0.55 (-27.9% Y/Y) and the consensus Revenue Estimate is $10.24M (+134.9% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions ...

MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a co...

CHEMOCENTRYX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ChemoCentryx, Inc. - CCXI CHEMOCENTRYX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Invest...

The second part to my series on the Biotechnology industry will be finding the necessary skills to research companies. The concepts are simple, but the information is sometimes difficult to find, and so I provide some examples. The five companies I analyze are just examples, and u...